NewEdge Advisors LLC Increases Stock Position in AbbVie Inc. $ABBV

NewEdge Advisors LLC raised its stake in shares of AbbVie Inc. (NYSE:ABBV) by 0.9% in the 1st quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 632,140 shares of the company’s stock after purchasing an additional 5,648 shares during the period. NewEdge Advisors LLC’s holdings in AbbVie were worth $137,483,000 as of its most recent filing with the Securities & Exchange Commission.

Other large investors have also recently made changes to their positions in the company. Litman Gregory Wealth Management LLC purchased a new position in shares of AbbVie in the fourth quarter valued at $28,000. Imprint Wealth LLC raised its stake in AbbVie by 56.2% during the fourth quarter. Imprint Wealth LLC now owns 125 shares of the company’s stock valued at $29,000 after purchasing an additional 45 shares in the last quarter. IFC & Insurance Marketing Inc. purchased a new stake in AbbVie during the fourth quarter valued at $31,000. Legacy Wealth Managment LLC ID lifted its position in AbbVie by 115.9% during the fourth quarter. Legacy Wealth Managment LLC ID now owns 136 shares of the company’s stock valued at $31,000 after purchasing an additional 73 shares during the last quarter. Finally, WestEnd Advisors LLC grew its stake in shares of AbbVie by 160.4% in the 4th quarter. WestEnd Advisors LLC now owns 138 shares of the company’s stock worth $32,000 after buying an additional 85 shares in the last quarter. 70.23% of the stock is owned by institutional investors.

AbbVie Trading Up 0.9%

ABBV stock opened at $245.98 on Thursday. The stock has a market cap of $434.59 billion, a PE ratio of 69.49, a P/E/G ratio of 0.81 and a beta of 0.30. AbbVie Inc. has a 12 month low of $190.75 and a 12 month high of $267.47. The company has a 50-day moving average price of $240.90 and a 200 day moving average price of $224.61.

AbbVie (NYSE:ABBV) last posted its quarterly earnings data on Friday, July 31st. The company reported $3.65 earnings per share for the quarter, topping analysts’ consensus estimates of $3.61 by $0.04. The company had revenue of $16.99 billion for the quarter, compared to analyst estimates of $16.80 billion. AbbVie had a net margin of 9.80% and a negative return on equity of 422.07%. The firm’s revenue for the quarter was up 10.2% on a year-over-year basis. During the same period in the prior year, the company posted $2.97 EPS. AbbVie has set its Q3 2026 guidance at 3.840-3.880 EPS. Sell-side analysts forecast that AbbVie Inc. will post 14.06 EPS for the current year.

AbbVie Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Friday, August 14th. Stockholders of record on Wednesday, July 15th will be issued a $1.73 dividend. This represents a $6.92 annualized dividend and a dividend yield of 2.8%. The ex-dividend date is Wednesday, July 15th. AbbVie’s dividend payout ratio is presently 195.48%.

Key Headlines Impacting AbbVie

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: AbbVie priced approximately $9.9 billion of senior notes to help fund an acquisition. While the financing increases interest obligations, it provides capital to pursue a transaction intended to strengthen the company’s growth profile. AbbVie prices $9.9B senior notes to fund acquisition
• Positive Sentiment: Analyst sentiment remains favorable. Erste Group upgraded AbbVie from “hold” to “buy,” while Cantor Fitzgerald raised its price target to $285, implying additional upside from recent trading levels. Cantor Fitzgerald boosts AbbVie price target
• Positive Sentiment: Second-quarter results exceeded expectations: revenue increased 10.2% year over year to $16.99 billion, and adjusted EPS of $3.65 surpassed the $3.61 consensus estimate. Growth in immunology and neuroscience helped offset concerns about the post-Humira transition, while third-quarter EPS guidance of $3.84–$3.88 indicates continued earnings momentum. AbbVie Q2 results and outlook
• Positive Sentiment: The FDA accepted Allergan Aesthetics’ supplemental application for BOTOX Cosmetic in masseter muscle prominence, expanding a major product into a potential new aesthetic indication. Approval could broaden BOTOX’s revenue opportunity, although the application still requires regulatory review. FDA accepts BOTOX Cosmetic application
• Positive Sentiment: Canada’s drug agency recommended conditional reimbursement of UBRELVY for acute migraine treatment, potentially improving access and supporting international growth for the newer migraine medicine. UBRELVY reimbursement recommendation
• Neutral Sentiment: RemeGen forecast a significant profit turnaround, citing stronger drug sales and an AbbVie licensing deal. The development supports AbbVie’s partnered pipeline but is unlikely to materially affect near-term results. RemeGen licensing update
• Negative Sentiment: Valuation remains a risk. Commentary noted ABBV’s trailing P/E near 70 and a model estimating fair value roughly $50 below the current level, raising concerns that much of the positive outlook may already be reflected in the stock. AbbVie year-end price prediction

Analyst Ratings Changes

A number of analysts have recently weighed in on the stock. Erste Group Bank upgraded shares of AbbVie from a “hold” rating to a “buy” rating in a report on Wednesday. Royal Bank Of Canada lifted their price target on AbbVie from $260.00 to $280.00 and gave the stock an “outperform” rating in a research report on Friday, July 10th. Wells Fargo & Company boosted their price objective on AbbVie from $260.00 to $295.00 and gave the stock an “overweight” rating in a research note on Friday, July 10th. Morgan Stanley reaffirmed an “overweight” rating and issued a $296.00 price objective on shares of AbbVie in a research note on Monday. Finally, Citigroup lifted their target price on AbbVie from $230.00 to $260.00 and gave the stock a “neutral” rating in a report on Wednesday, July 15th. Two investment analysts have rated the stock with a Strong Buy rating, nineteen have given a Buy rating and four have given a Hold rating to the company. According to data from MarketBeat.com, AbbVie currently has a consensus rating of “Moderate Buy” and an average price target of $272.76.

AbbVie Company Profile

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.